Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial

Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial

Background Patients with recurrent glioblastoma (rGB) have a poor prognosis with a median overall survival (OS) of 30–39 weeks in prospective clinical trials. Intravenous administration of programmed cell death protein 1 and cytotoxic T-lymphocyte-associated antigen 4 inhibitors has low activity in...

Full description

Saved in:
Bibliographic Details
Main Authors: Mark Kockx, Bart Neyns, Julia Katharina Schwarze, Gil Awada, Laura Seynaeve, Anne-Marie Vanbinst, Alex Michotte, Hendrik Everaert, Johnny Duerinck, Ramses Forsyth, Jens Tijtgat, Freya Vaeyens, Cleo Bertels, Wietse Geens, Samuel Klein, Louise Cras, Nicky D’Haene, Ben Caljon, Isabelle Salmon, Michaël Bruneau, Sonia Van Dooren
Format: Article
Language:English
Published: BMJ Publishing Group 2021-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/6/e002296.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/9/6/e002296.full

Similar Items